DEFINITION
What is Mistletoe ?
European mistletoe (Viscum album L.) is a hemiparasitic plant used in integrative oncology as a supportive — not curative — treatment alongside conventional cancer care. It is distinct from American mistletoe and should not be confused with it.
Mistletoe extracts contain active compounds called lectins and viscotoxins. In laboratory and animal studies, these compounds have demonstrated immune-stimulating and anti-tumor activity. In clinical studies, the strongest and most consistent finding is an improvement in quality of life for patients undergoing cancer treatment.
Mistletoe therapy is not an alternative to conventional oncology. It is offered at GWCIM as a complement to chemotherapy, radiation, surgery, or immunotherapy — never as a replacement.
Qualifications & Background
Mistletoe therapy at GWCIM is prescribed and supervised by medical doctors and licensed naturopathic physicians with training in integrative oncology. All patients undergo a formal medical intake and are monitored with regular laboratory assessments throughout treatment.
INDICATIONS
What conditions does it help with?
ADVANTAGE
Why Mistletoe at GWCIM?
GWCIM has offered mistletoe therapy as part of its integrative oncology program since the center's early years. Our naturopathic physicians are experienced in selecting appropriate preparations and dosing schedules based on each patient's cancer type, treatment history, and current health status. Patients benefit from GWCIM's broader integrative team — including physicians, nutritionists, and mental health providers — who can address the full range of challenges that arise during cancer care.
APPROACH
Our Process
Every patient begins with a thorough consultation to review their oncology history, current treatment plan, and recent laboratory work. This assessment determines whether mistletoe therapy is appropriate, and if so, which preparation and dosing approach best fits the patient's situation.
Mistletoe therapy has been studied primarily in adults with solid tumor malignancies receiving active conventional treatment or best supportive care. Clinical evidence supports its potential role in improving the quality of life for patients with:
- Non-small cell lung cancer
- Breast cancer
- Ovarian cancer
- Pancreatic cancer
The therapy may also be considered for patients who have completed active treatment and are focused on recovery and long-term well-being. Suitability is determined individually at consultation.
Patients are trained to self-administer mistletoe at home on a schedule determined by their provider. All patients receiving mistletoe therapy are seen by their GWCIM physician approximately once a month for reassessment. Communication with the patient's oncology team is encouraged and facilitated when appropriate.
Care Options
Initial Mistletoe Consultation
Full oncology intake, laboratory review, eligibility assessment, and treatment planning with a GWCIM naturopathic physician.
Ongoing Treatment and Monitoring
Monthly follow-up appointments; laboratory monitoring as indicated; dose adjustments as needed.
In-Person Only
This service requires in-person visits at our Washington, DC clinic at 908 New Hampshire Ave NW, Suite 200.
EXPERTISE
Recommended Providers
LEARN MORE
What to expect as a patient
- Initial Consultation: A full intake with one of our naturopathic physicians to review your diagnosis, current treatment, medical history, and recent labs (metabolic panel and complete blood count required). This appointment determines eligibility and establishes your treatment plan.
- Training: Patients who are candidates for home self-administration are trained in the correct technique before beginning independent use.
- Ongoing Monitoring: Follow-up appointments approximately once per month to assess response, review labs, and adjust dosing if needed.
- Coordination of Care: We communicate with your oncologist as appropriate. We do not recommend mistletoe therapy in isolation from your primary cancer care team.
Q&A
Q&A
No. Mistletoe extracts are not currently approved by the U.S. Food and Drug Administration for the treatment of cancer or any other condition. They are available in the United States under the oversight of a licensed physician, and clinical trials are ongoing. In Europe, mistletoe preparations have been used in oncology settings for over a century and are widely prescribed there.
The most reliable clinical evidence supports mistletoe therapy's potential to improve quality of life — specifically appetite, sleep, energy, and general wellbeing — in patients with certain cancers receiving conventional treatment. Evidence regarding tumor response, recurrence, or survival is less consistent and methodologically more limited. We will discuss the current state of research with you directly at your consultation.
The most common side effect is a local reaction at the injection site — redness, mild swelling, or warmth — which is generally considered a sign of immune activation rather than a problem. Mild flu-like symptoms (fatigue, low-grade fever) occasionally occur, particularly at the start of treatment. Serious adverse events are rare when therapy is properly supervised and dosed. A full adverse effects profile will be reviewed at your consultation.
EDUCATION